CD19 targeting chimeric antigen receptor and application thereof

A chimeric antigen receptor and application technology, applied in the field of biomedicine, can solve the problem that the immune system cannot remove tumors well, reduce immunogenicity, etc., and achieve the effects of prolonging survival time, high safety and high expression
CN112079934AActive Publication Date: 2020-12-15JUVENTAS CELL THERAPY LTD
6 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
JUVENTAS CELL THERAPY LTD
Publication Date
2020-12-15

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises an amino acid sequence shown in SEQ ID NO. 1. The application also provides nucleic acids encoding the chimeric antigen receptor, vectors comprising the nucleic acids, immune effector cells comprising the chimeric antigen receptor, the nucleic acid molecules and / or the vectors, methods of preparing the immune effector cells, compositions comprising the immune effector cells, and uses of the chimeric antigen receptor.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] This application relates to the field of biomedicine, in particular to a chimeric antigen receptor targeting CD19 and its use. Background technique

[0002] The clinical treatment of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and B-cell lymphoma is currently based on chemotherapy, stem cell transplantation and biological therapy. The key point that is difficult to overcome, as a new treatment strategy, cellular immunotherapy of tumors has become a research hotspot today. CD19 is expressed on the surface of almost all B cell tumor cells, while other parenchymal cells and hematopoietic stem cells are almost not expressed.

[0003] Tumor cells generate immune escape by down-regulating the expression of molecules involved in T cell recognition and antigen response, reducing immunogenicity, etc., so that the body's immune system cannot clear the tumor well. Studies have found that chimeric antigen receptor T cells (CAR-T cells)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More